Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis
Open Access
- 12 September 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-12
Abstract
Nonischemic cardiomyopathy (NISCM) is a clinical challenge with limited therapeutic targets. This study aims to identify promising drug targets for NISCM. We utilized cis-pQTLs from the deCODE study, which includes data from 35,559 Icelanders, and SNPs from the FinnGen study, which includes data from 1,754 NISCM cases and 340,815 controls of Finnish ancestry. Mendelian randomization (MR) analysis was performed to estimate the causal relationship between circulating plasma protein levels and NISCM risk. Proteins with significant associations underwent false discovery rate (FDR) correction, followed by Bayesian colocalization analysis. The expression of top two proteins, LILRA5 and NELL1, was further analyzed using various NISCM datasets. Descriptions from the Human Protein Atlas (HPA) validated protein expression. The impact of environmental exposures on LILRA5 was assessed using the Comparative Toxicogenomics Database (CTD), and molecular docking identified the potential small molecule interactions. MR analysis identified 255 circulating plasma proteins associated with NISCM, with 16 remaining significant after FDR correction. Bayesian colocalization analysis identified LILRA5 and NELL1 as significant, with PP.H4 > 0.8. LILRA5 has a protective effect (OR = 0.758, 95% CI, 0.670–0.857) while NELL1 displays the risk effect (OR = 1.290, 95% CI, 1.199–1.387) in NISCM. Decreased LILRA5 expression was found in NISCM such as diabetic, hypertrophic, dilated, and inflammatory cardiomyopathy, while NELL1 expression increased in hypertrophic cardiomyopathy. HPA data indicated high LILRA5 expression in neutrophils, macrophages and endothelial cells within normal heart and limited NELL1 expression. Immune infiltration analysis revealed decreased neutrophil in diabetic cardiomyopathy. CTD analysis identified several small molecules that affect LILRA5 mRNA expression. Among these, Estradiol, Estradiol-3-benzoate, Gadodiamide, Topotecan, and Testosterone were found to stably bind to the LILRA5 protein at the conserved VAL-15 or THR-133 residues in the Ig-like C2 domain. Based on European Ancestry Cohort, this study reveals that LILRA5 and NELL1 are potential therapeutic targets for NISCM, with LILRA5 showing particularly promising prospects in diabetic cardiomyopathy. Several small molecules interact with LILRA5, implying potential clinical implication.Keywords
All Related Versions
Funding Information
- Innovative Research Projects for Graduate Students in Hainan Province (Qhyb2022-140)
- National Natural Science Foundation of China (U220A20270, 82060053, 82260083)
- Cardiovascular Disease Research Science Innovation Group of Hainan Medical University
- the innovational fund for scientific and technological personnel of Hainan Province (KJRC2023B07)
- Hainan Key Research and Development Project (ZDYF2020122, ZDYF2022SHFZ038)
This publication has 43 references indexed in Scilit:
- A Novel Genomic Signature with Translational Significance for Human Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2015
- Chemistry: Chemical con artists foil drug discoveryNature, 2014
- Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary StatisticsPLOS Genetics, 2014
- Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized DataGenetic Epidemiology, 2013
- The G-protein-coupled estrogen receptor GPER in health and diseaseNature Reviews Endocrinology, 2011
- Avoiding bias from weak instruments in Mendelian randomization studiesInternational Journal of Epidemiology, 2011
- Stratified false discovery control for large‐scale hypothesis testing with application to genome‐wide association studiesGenetic Epidemiology, 2006
- Contemporary Definitions and Classification of the CardiomyopathiesCirculation, 2006
- N,N,N′,N′-Tetrakis(2-pyridylmethyl)-ethylenediamine Improves Myocardial Protection against Ischemia by Modulation of Intracellular Ca2+ HomeostasisThe Journal of Pharmacology and Experimental Therapeutics, 2005
- LIR9, an immunoglobulin-superfamily–activating receptor, is expressed as a transmembrane and as a secreted moleculeBlood, 2003